GSK Breakout Trade – Clean Setup AheadPattern: Bullish breakout from descending wedge
Entry Zone: Around $4.83–$4.97
Stop Loss: Just below $4.70 (trendline + horizontal support)
Target: $5.18 (green resistance level)
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
40.75 MXN
68.60 B MXN
835.91 B MXN
2.02 B
About GSK PLC ORD GBP0.3125
Sector
Industry
CEO
Emma N. Walmsley
Website
Headquarters
London
FIGI
BBG000BT3T60
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Related stocks
$GSKA potential "ABC" pattern has been located here at a level where two previous support levels were broken. Price is near the 11-2023 support level. Looking for a retracement here to two targets overtime.
GSK 1-2 wk swing IdeaNYSE:GSK has set of a daily trigger with a 5/10 ema crossover after a positive earnings report.
During my planning for this idea, I needed to zoom WAY out to the monthly chart in order to understand these levels a bit more. Screen shot of the monthly below:
It turns out that last week's close
GSKNot a recommendation. Held this for a while with very little movement, now GSK as started going up, div yield is over 3.3%
Long GSK - Euro Drug Hype Cycle approachesPlaying short term trade presuming positive news in a week or two.
Shares would return to the range highs near $37.00
Ex-Dividend Date later this week
GSK (GSK) Outperformed Market ReturnsIn the latest trading session, GSK (GSK) closed at $37.10, marking a +1.23% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 0.39%.
Prior to today's trading, shares of the dru
GSK looking bullish! Buy volume at resistance at this point in the falling channel should help propel the price to an initial measured target if $47 which would be thr breakout point of an even bigger bullish macro setup.
GSK with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for GSK after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
Long Glaxo Smith Kline (NAS:GSK) looks very good risk returnUsing longer term Auction Market Theory to construct longer term meaningful #VolumeProfiles can sometimes provide exceptional risk reward setups.
One has just popped up in GSK according to my read anyway.
Now price has returned into the longer term Value Area there's a very good chance price will
$GSK: Weekly trend signalGreat reward to risk in this weekly chart setup in $GSK, worth a shot, you can probably play it with options to not allocate too much capital in this idea and have limited downside risk. An ITM put spread or some kind of Iron Butterfly OTM can both reap the passage of time profiting from Theta drop
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GSK6023692
GlaxoSmithKline Capital Plc FRN 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
GSK6023693
GlaxoSmithKline Capital, Inc. 4.875% 15-APR-2035Yield to maturity
—
Maturity date
Apr 15, 2035
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043Yield to maturity
—
Maturity date
Mar 18, 2043
GSK6023695
GlaxoSmithKline Capital, Inc. 4.5% 15-APR-2030Yield to maturity
—
Maturity date
Apr 15, 2030
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038Yield to maturity
—
Maturity date
May 15, 2038
GSK6023691
GlaxoSmithKline Capital Plc 4.315% 12-MAR-2027Yield to maturity
—
Maturity date
Mar 12, 2027
XS293369143
GSK CAP B.V. 24/31 MTNYield to maturity
—
Maturity date
Nov 19, 2031
GX5B
GLAXOSM.CAP. MTN 17/26Yield to maturity
—
Maturity date
Sep 12, 2026
XS217060907
GLAXOSM.CAP. MTN 20/35MTNYield to maturity
—
Maturity date
May 12, 2035
US377373AH8
GLAXOSM.CAP. 19/29Yield to maturity
—
Maturity date
Jun 1, 2029
XS168152035
GLAXOSM.CAP. MTN 17/29Yield to maturity
—
Maturity date
Sep 12, 2029
See all GSK/N bonds
Curated watchlists where GSK/N is featured.
Female-led stocks: Who rules the world?
34 No. of Symbols
UK stocks: Best of British
28 No. of Symbols
See all sparks